Medical Pharmacology: Chapter 15: Local Anesthetics -- Module 2: Clinical Pharmacology of Individual Agents, Adjuvants, Toxicology, and Drug Interactions

Chapter 15: Local Anesthetics — Module 2: Clinical Pharmacology of Individual Agents, Adjuvants, Toxicology, and Drug Interactions
Tier: Clinical Vignette (11 questions)

1. A 28-year-old woman at 28 weeks gestation requires emergency appendectomy. She has an existing labor epidural catheter in situ. The anesthesiologist plans to use the epidural catheter to provide surgical anesthesia, avoiding general anesthesia to minimize fetal drug exposure. She selects bupivacaine for epidural conversion. Which of the following correctly identifies the appropriate bupivacaine concentration for this indication and the pharmacologic reason the highest available concentration is specifically excluded?

A) Bupivacaine 0.75% is the appropriate choice because the urgency of the procedure requires the deepest and most rapidly-onset surgical block achievable; the risk of maternal cardiovascular toxicity at this concentration is acceptable given the surgical necessity, and the fetal risk from general anesthesia exceeds the maternal risk from concentrated bupivacaine.
B) Bupivacaine 0.25% is the maximum concentration appropriate for surgical anesthesia in obstetric patients; concentrations above 0.25% produce thoracic sympathetic blockade severe enough to compromise uteroplacental blood flow, which is the primary contraindication to higher concentrations in this setting.
C) Bupivacaine 0.5% is appropriate for surgical epidural anesthesia in this patient; bupivacaine 0.75% is specifically contraindicated for obstetric epidural use because the 1984 FDA withdrawal followed multiple maternal deaths from refractory cardiovascular collapse after inadvertent intravascular injection of this concentrated preparation — the higher milligram-per-milliliter load delivered by 0.75% makes accidental intravascular injection catastrophically dangerous in a setting where the engorged epidural venous plexus of pregnancy increases the probability of intravascular catheter placement.
D) Any concentration of bupivacaine is contraindicated for epidural use beyond the first trimester because bupivacaine crosses the placenta at all clinically used concentrations and produces fetal cardiac sodium channel blockade; a chloroprocaine-based epidural conversion is the only pharmacologically safe option in a patient at 28 weeks gestation.
E) Bupivacaine 0.75% and 0.5% carry equivalent maternal cardiovascular risk; the reason 0.75% is avoided in obstetric practice is not cardiovascular but neonatal — bupivacaine at 0.75% concentration produces a higher fetal:maternal plasma ratio than 0.5% due to concentration-dependent saturation of maternal protein binding, increasing fetal drug exposure to levels associated with neonatal cardiovascular depression.

ANSWER: C

Rationale:

Option C is correct. Bupivacaine 0.5% is the appropriate concentration for surgical epidural anesthesia in this obstetric patient, including for cesarean delivery. Bupivacaine 0.75% is formally contraindicated for obstetric epidural use based on the 1984 FDA withdrawal following a series of maternal deaths. The mechanism was inadvertent intravascular injection — either through unrecognized intravascular catheter placement or through injection into an epidural vein — of a large volume of the concentrated preparation. The epidural venous plexus is engorged during pregnancy due to aortocaval compression and increased venous volume, increasing the likelihood of intravascular catheter tip placement. If 0.75% bupivacaine is injected intravascularly, the milligram bolus delivered per unit volume is 50% greater than the same volume of 0.5% bupivacaine, and the resulting bupivacaine plasma concentration rapidly exceeds the threshold for cardiac Nav1.5 sodium channel blockade with its fast-in, slow-out kinetics — producing refractory ventricular fibrillation and cardiovascular collapse before the warning signs of intravascular injection can be recognized and acted upon. The principle established is that the highest available concentration of a potent cardiotoxic agent should not be used routinely in a clinical setting where inadvertent intravascular injection is both probable and catastrophic. For this patient undergoing appendectomy, bupivacaine 0.5% with appropriate test dosing and incremental injection technique is both safe and effective.

Option A: Option A is incorrect; surgical urgency does not override the FDA contraindication for 0.75% bupivacaine in obstetric epidural use — the risk of maternal cardiovascular collapse from intravascular injection at this concentration is not acceptable under any clinical circumstance, and 0.5% bupivacaine provides equivalent surgical anesthesia.
Option B: Option B is incorrect; while 0.25% bupivacaine is used for labor analgesia, it provides insufficient motor and sensory block for abdominal surgery; uteroplacental blood flow compromise from thoracic sympathectomy is a concern at any epidural concentration and is managed with fluid preloading and vasopressors, not by restricting concentration below 0.5%.
Option D: Option D is incorrect; bupivacaine at clinical epidural concentrations does produce some placental transfer, but fetal cardiac sodium channel blockade at the doses used for epidural anesthesia is not a clinically recognized risk; the primary obstetric concern for bupivacaine is maternal, not fetal direct cardiac toxicity.
Option E: Option E is incorrect; bupivacaine 0.75% is not avoided because of concentration-dependent protein binding saturation increasing fetal drug exposure — the contraindication is maternal cardiovascular safety from intravascular injection, not fetal drug exposure.

2. A 44-year-old man with treatment-resistant depression is scheduled for septoplasty and functional endoscopic sinus surgery. His current medications include phenelzine (a non-selective, irreversible monoamine oxidase inhibitor — MAOI — antidepressant) and lithium. The ENT surgeon requests cocaine 4% topical solution for nasal mucosal anesthesia and vasoconstriction. The anesthesiologist reviews the medication list. Which of the following correctly describes the management of this drug interaction and its pharmacologic basis?

A) Cocaine may be used safely in this patient because phenelzine inhibits MAO-A, which metabolizes serotonin and norepinephrine in the CNS but not in peripheral sympathetic synapses; cocaine's norepinephrine reuptake inhibition at peripheral nasal mucosal sympathetic terminals therefore does not interact with phenelzine's mechanism.
B) Cocaine should be replaced with epinephrine-containing lidocaine solution, which provides equivalent mucosal vasoconstriction via direct α₁-adrenergic receptor stimulation; unlike cocaine, lidocaine with epinephrine does not inhibit norepinephrine reuptake and therefore poses no interaction risk with phenelzine.
C) The interaction between cocaine and phenelzine is a pharmacokinetic interaction rather than pharmacodynamic; phenelzine inhibits the MAO-mediated first-pass metabolism of cocaine in the nasal mucosa, increasing systemic cocaine bioavailability; the interaction can be safely managed by reducing the cocaine dose by 50% while maintaining the same topical concentration.
D) Cocaine is contraindicated with phenelzine, but the washout period for phenelzine is only 24 hours because MAO-A inhibition by phenelzine is reversible; if the procedure can be delayed by 24 hours after phenelzine cessation, cocaine can be used without interaction risk.
E) Cocaine is contraindicated in this patient; phenelzine is a non-selective, irreversible MAOI that prevents MAO-mediated degradation of norepinephrine at sympathetic synapses; when cocaine simultaneously blocks norepinephrine reuptake, the two mechanisms combine to produce dangerous accumulation of norepinephrine with no clearance pathway — carrying serious risk of hypertensive crisis, severe tachyarrhythmia, and hyperpyrexia; the appropriate substitution is oxymetazoline for vasoconstriction with lidocaine or tetracaine for topical anesthesia.

ANSWER: E

Rationale:

Option E is correct. The cocaine-MAOI combination is one of the most dangerous drug interactions involving local anesthetics in clinical practice. Cocaine inhibits the presynaptic norepinephrine reuptake transporter (NET), preventing clearance of released norepinephrine from sympathetic synapses. Under normal physiologic conditions, norepinephrine that escapes reuptake is degraded by monoamine oxidase (MAO). Phenelzine is a non-selective, irreversible MAOI — it permanently inactivates both MAO-A and MAO-B until new enzyme is synthesized, a process requiring 2–3 weeks. When both clearance mechanisms — reuptake by NET and degradation by MAO — are simultaneously blocked, norepinephrine released by sympathetic nerve activity accumulates to dangerous concentrations throughout the body, producing severe hypertension, tachyarrhythmia, hyperpyrexia, and risk of intracranial hemorrhage or myocardial infarction. This reaction can occur even with topical cocaine applied to nasal mucosa, because systemic absorption from this highly vascular tissue is substantial and rapid. The procedure should be performed using oxymetazoline (a direct α₁/α₂-adrenergic agonist that provides nasal vasoconstriction without affecting norepinephrine reuptake or metabolism) combined with lidocaine or tetracaine for topical anesthesia. Epinephrine-containing solutions also require caution with MAOIs, though the interaction is less consistent than the cocaine-MAOI combination.

Option A: Option A is incorrect; phenelzine inhibits MAO throughout the body, including at peripheral sympathetic nerve terminals — there is no compartmentalization of MAO-A activity to the CNS that would protect against peripheral sympathomimetic crises.
Option B: Option B is incorrect; epinephrine-containing lidocaine solutions carry their own interaction risk with MAOIs because MAO is involved in catecholamine degradation — adding exogenous epinephrine to a patient on an irreversible MAOI can produce an exaggerated vasopressor response; this substitution does not eliminate the risk and should be used with great caution if at all.
Option C: Option C is incorrect; the cocaine-phenelzine interaction is pharmacodynamic, not pharmacokinetic — MAO does not metabolize cocaine in the nasal mucosa; cocaine is an ester metabolized by plasma pseudocholinesterase.
Option D: Option D is incorrect; phenelzine is an irreversible MAOI — it forms a covalent bond with the MAO enzyme and cannot be washed out by stopping the drug; full enzyme activity is restored only when new MAO enzyme is synthesized over 2–3 weeks, not 24 hours.

3. A 71-year-old man with Child-Pugh A hepatic cirrhosis underwent major hepatic resection 18 hours ago and has been receiving continuous epidural ropivacaine 0.2% at 12 mL/hour (24 mg/hour) for postoperative analgesia. The nursing staff pages the on-call resident because the patient has become progressively confused over the past two hours and is complaining of tinnitus and a metallic taste. His vital signs show heart rate 98, blood pressure 152/88, respiratory rate 18, and SpO₂ 97% on 2L nasal cannula. Which of the following correctly identifies the most likely diagnosis and the immediate management priority?

A) This presentation is consistent with ropivacaine systemic toxicity (local anesthetic systemic toxicity — LAST) from plasma accumulation; the combination of an infusion rate at the upper end of the safe range, hepatic CYP enzyme impairment from cirrhosis, and 18 hours of continuous infusion has likely produced progressive ropivacaine plasma accumulation to CNS-toxic concentrations; the immediate action is to stop the epidural infusion, prepare lipid emulsion for potential cardiovascular progression, obtain IV access, and monitor continuously for seizure and cardiovascular deterioration.
B) This presentation is most consistent with hepatic encephalopathy precipitated by the surgical stress and blood loss of hepatic resection; tinnitus and metallic taste are not features of ropivacaine toxicity at standard infusion doses and should not be attributed to the epidural infusion; the immediate action is to check ammonia levels, hold enteral feedings, and consult hepatology.
C) This presentation is most consistent with opioid-related neurotoxicity from the systemic analgesics prescribed alongside the epidural; confusion and tinnitus are features of opioid accumulation in hepatically impaired patients; the epidural infusion is not the cause, and the immediate action is to administer naloxone 0.4 mg IV and reassess.
D) This presentation is consistent with hypoglycemia from reduced hepatic gluconeogenesis in the post-operative period following major hepatic resection; tinnitus and confusion are recognized features of neuroglycopenia; the immediate action is to check a point-of-care glucose and administer dextrose 50% IV if glucose is below 60 mg/dL.
E) This presentation is consistent with sepsis-related encephalopathy from a likely anastomotic leak or bile leak following hepatic resection; the metallic taste reflects accumulation of bile acids crossing the blood-brain barrier during hepatic decompensation; the immediate action is to obtain blood cultures, CT abdomen with contrast, and activate the surgical team.

ANSWER: A

Rationale:

Option A is correct. The clinical presentation — progressive confusion, tinnitus, and metallic taste in a patient receiving a continuous ropivacaine epidural infusion — is the classic early CNS toxicity syndrome of local anesthetic systemic toxicity (LAST). Tinnitus and metallic taste are well-established early warning symptoms of rising plasma local anesthetic concentrations, reflecting preferential sodium channel blockade in the CNS at concentrations below those required for cardiovascular toxicity. The pharmacokinetic context makes ropivacaine accumulation highly plausible: ropivacaine is an amide local anesthetic dependent on hepatic CYP1A2 and CYP3A4 for clearance; this patient has hepatic cirrhosis (Child-Pugh A) reducing CYP enzyme activity; the infusion rate of 24 mg/hour is at the upper end of the recommended continuous epidural range; and 18 hours of infusion represents substantial cumulative exposure. Progressive ropivacaine plasma accumulation during a continuous infusion in a hepatically impaired patient is a predictable pharmacokinetic consequence that was not corrected for by pre-emptive dose reduction. The immediate management priority is to stop the epidural infusion to halt further drug delivery, establish reliable IV access, prepare lipid emulsion for potential cardiovascular progression (ventricular dysrhythmia can follow the CNS prodrome), and monitor continuously. If seizures develop, benzodiazepines are the first-line treatment. If cardiovascular compromise develops, lipid emulsion 1.5 mL/kg IV bolus is the definitive intervention.

Option B: Option B is incorrect; while hepatic encephalopathy is a legitimate concern in this patient, the specific triad of tinnitus, metallic taste, and confusion in a patient on a continuous local anesthetic infusion is pathognomonic of LAST — hepatic encephalopathy does not produce tinnitus or metallic taste.
Option C: Option C is incorrect; tinnitus and metallic taste are not features of opioid toxicity, which typically presents with sedation, miosis, and respiratory depression; these symptoms specifically characterize local anesthetic CNS toxicity.
Option D: Option D is incorrect; hypoglycemia produces diaphoresis, tremor, and neuroglycopenic confusion, but tinnitus and metallic taste are not characteristic features of hypoglycemia; checking glucose is reasonable but not the primary concern given the strong pharmacokinetic explanation for LAST.
Option E: Option E is incorrect; post-hepatic resection bile or anastomotic leak is an important complication but presents with fever, peritoneal signs, and hemodynamic instability — tinnitus and metallic taste are not features of sepsis-related encephalopathy or bile acid accumulation.

4. A 52-year-old woman with obsessive-compulsive disorder on fluvoxamine 200 mg daily is scheduled for open colectomy. The anesthesiologist plans a thoracic epidural for intraoperative and postoperative analgesia and is selecting between ropivacaine 0.2% and bupivacaine 0.125% for the continuous postoperative infusion. She is aware that fluvoxamine is a potent inhibitor of CYP1A2 (cytochrome P450 1A2). Which of the following correctly applies the drug interaction pharmacology to the agent selection and infusion rate decisions for this patient?

A) The CYP1A2 interaction is clinically irrelevant for both agents because epidural local anesthetics achieve their analgesic effect at the neural level before entering the systemic circulation; hepatic CYP metabolism only affects drug that has been absorbed systemically, and epidural drug absorption is insufficient to produce clinically meaningful plasma concentrations at continuous infusion analgesic doses.
B) Bupivacaine should be selected over ropivacaine because bupivacaine's higher protein binding (~95%) means less free drug is available for CYP1A2-mediated metabolism; fluvoxamine's inhibitory effect on CYP1A2 therefore produces a smaller proportional increase in free bupivacaine concentration than it would for ropivacaine, making bupivacaine the safer choice under CYP1A2 inhibition.
C) Both ropivacaine and bupivacaine are equally affected by fluvoxamine because both agents depend entirely on CYP1A2 for their hepatic clearance; the infusion rate of whichever agent is selected must be reduced by 90% to account for near-complete CYP1A2 inhibition by therapeutic fluvoxamine doses.
D) Ropivacaine is more dependent on CYP1A2 for its hepatic clearance than bupivacaine; fluvoxamine-mediated CYP1A2 inhibition will therefore reduce ropivacaine clearance more substantially than bupivacaine clearance, leading to higher steady-state ropivacaine plasma concentrations at any given infusion rate; if ropivacaine is used, the infusion rate should be reduced compared to standard dosing, and monitoring for early CNS toxicity signs should be heightened; alternatively, bupivacaine may be preferred as it is less affected by this specific interaction.
E) The interaction between fluvoxamine and ropivacaine is beneficial in this clinical context because reduced ropivacaine clearance from CYP1A2 inhibition raises steady-state plasma concentrations, supplementing the epidural neural block with systemic analgesic plasma levels of ropivacaine; the standard infusion rate should therefore be maintained or increased to take advantage of this pharmacokinetic enhancement.

ANSWER: D

Rationale:

Option D is correct. Ropivacaine and bupivacaine are both amide local anesthetics metabolized by hepatic CYP3A4 and CYP1A2, but they differ in their relative dependence on each isoform — ropivacaine is substantially more CYP1A2-dependent than bupivacaine, which relies more heavily on CYP3A4. Fluvoxamine is a potent and selective CYP1A2 inhibitor at therapeutic antidepressant doses (200 mg daily is at the high end of the therapeutic range and produces near-maximal CYP1A2 inhibition). In a patient receiving a continuous ropivacaine epidural infusion, this drug interaction substantially reduces ropivacaine's hepatic clearance, causing progressive plasma accumulation toward a higher steady-state concentration than would be achieved without fluvoxamine. This elevated steady-state concentration narrows the margin between therapeutic and toxic plasma levels and increases the risk of CNS toxicity signs (tinnitus, circumoral numbness, confusion) emerging during a prolonged postoperative infusion. The practical clinical options are: (1) use bupivacaine instead, since bupivacaine is less CYP1A2-dependent and is less affected by fluvoxamine; or (2) use ropivacaine at a reduced infusion rate with enhanced monitoring. Either choice is defensible; awareness of the interaction and appropriate adjustment is mandatory.

Option A: Option A is incorrect; epidural local anesthetics are absorbed into the systemic circulation from the epidural venous plexus, and plasma concentrations during continuous infusions are clinically significant — the drug interaction is pharmacologically real and clinically relevant.
Option B: Option B is incorrect; while bupivacaine's higher protein binding reduces the free fraction, protein binding does not reduce dependence on CYP1A2 for clearance — bound drug is eventually released and must be cleared; the relevant factor is which CYP isoform is responsible for clearance, not protein binding.
Option C: Option C is incorrect; neither ropivacaine nor bupivacaine depends entirely on CYP1A2 — both are also metabolized by CYP3A4; the inhibition is significant for ropivacaine but not absolute for either agent, and a 90% dose reduction is not warranted.
Option E: Option E is incorrect; accumulation of ropivacaine from impaired clearance does not provide beneficial systemic analgesia — it represents a toxicity risk; plasma ropivacaine concentrations high enough to provide systemic analgesia are above the therapeutic window for continuous epidural use and would carry CNS toxicity risk.

5. A 6-week-old male infant (weight 4.2 kg) underwent elective inguinal hernia repair under general anesthesia. Preoperatively, EMLA cream (lidocaine 2.5%/prilocaine 2.5%) was applied to the operative site and to both arms for IV cannulation — covering approximately 35% of his body surface area — under an occlusive dressing for 90 minutes. In the post-anesthesia care unit, the nurse notes SpO₂ of 88% on room air that does not improve with 100% oxygen via non-rebreather mask. The infant appears dusky. Arterial blood gas shows PaO₂ 245 mmHg (confirming adequate oxygenation) but co-oximetry reveals methemoglobin 18%. Which of the following correctly identifies the etiology and treatment?

A) The SpO₂ depression is caused by residual volatile anesthetic inhibiting hypoxic pulmonary vasoconstriction; the appropriate treatment is supportive oxygen supplementation and monitoring until the anesthetic agent clears, typically within 2–4 hours.
B) The infant has prilocaine-induced methemoglobinemia from EMLA application over an excessive body surface area; prilocaine's hepatic metabolite o-toluidine oxidized hemoglobin iron from Fe²⁺ to Fe³⁺, producing methemoglobin that cannot carry oxygen and causes cyanosis unresponsive to supplemental oxygen; at 18% methemoglobin with symptoms, the treatment is intravenous methylene blue 1–2 mg/kg, which reduces Fe³⁺ back to Fe²⁺ by providing an NADPH-dependent electron donor; neonates are particularly susceptible because fetal hemoglobin is more susceptible to oxidation and neonatal methemoglobin reductase activity is immature.
C) The cyanosis is caused by EMLA-induced laryngospasm from prilocaine-mediated inhibition of laryngeal sensory nerve conduction during tracheal extubation; the treatment is jaw thrust and positive pressure ventilation to relieve the laryngospasm, with succinylcholine 2 mg/kg IV if the airway cannot be opened manually.
D) The methemoglobinemia is caused by the lidocaine component of EMLA; lidocaine is metabolized to monoethylglycinexylidide (MEGX), which oxidizes hemoglobin at the concentrations achieved with large-area EMLA application in neonates; the treatment is intravenous methylene blue and discontinuation of all amide local anesthetics.
E) The SpO₂ depression reflects a pulse oximetry artifact from EMLA cream residue on the finger sensor; standard pulse oximetry cannot distinguish methemoglobin from oxyhemoglobin and overestimates arterial oxygen saturation in the presence of residual cream interference; the PaO₂ of 245 mmHg confirms adequate oxygenation and no treatment is required.

ANSWER: B

Rationale:

Option B is correct. This infant has prilocaine-induced methemoglobinemia from EMLA application over an excessive body surface area. The critical pharmacologic mechanism is that prilocaine is metabolized in the liver to o-toluidine, an aromatic amine that oxidizes the iron in hemoglobin from the ferrous (Fe²⁺) state — which binds oxygen — to the ferric (Fe³⁺) state, producing methemoglobin. Methemoglobin cannot bind or carry oxygen. This infant is particularly susceptible for two reasons: (1) fetal hemoglobin (HbF), which predominates at 6 weeks of age before conversion to adult hemoglobin (HbA), is more susceptible to o-toluidine-mediated oxidation; and (2) neonatal methemoglobin reductase activity is immature — typically reaching only 50–60% of adult activity — meaning the normal enzymatic pathway for reducing methemoglobin back to functional hemoglobin is substantially impaired. The 35% body surface area application for 90 minutes delivered a clinically significant o-toluidine exposure in this vulnerable neonate. The characteristic clinical finding is cyanosis unresponsive to supplemental oxygen (because the problem is impaired oxygen carrying, not inadequate inspired oxygen) with high PaO₂ on blood gas but low SpO₂ — standard pulse oximetry cannot distinguish methemoglobin from oxyhemoglobin, producing falsely low readings; co-oximetry directly measures methemoglobin. At 18% methemoglobin with clinical symptoms, treatment with intravenous methylene blue 1–2 mg/kg is indicated; methylene blue is reduced to leucomethylene blue by NADPH (from the hexose monophosphate shunt), which then reduces methemoglobin Fe³⁺ back to functional Fe²⁺ hemoglobin.

Option A: Option A is incorrect; volatile anesthetic-related hypoxic pulmonary vasoconstriction inhibition does not produce SpO₂ 88% unresponsive to 100% oxygen with a PaO₂ of 245 mmHg — this pattern is specific to methemoglobinemia or carboxyhemoglobinemia.
Option C: Option C is incorrect; EMLA does not produce laryngospasm through sensory nerve inhibition of the larynx, and the clinical presentation — cyanosis with high PaO₂ and elevated methemoglobin on co-oximetry — is inconsistent with laryngospasm.
Option D: Option D is incorrect; methemoglobinemia from EMLA is caused by the prilocaine component via its o-toluidine metabolite — lidocaine and its metabolite MEGX (monoethylglycinexylidide) do not oxidize hemoglobin iron; MEGX produces CNS toxicity at toxic plasma concentrations but not methemoglobinemia.
Option E: Option E is incorrect; the pulse oximetry reading is not an artifact — the low SpO₂ reflects genuine methemoglobin elevation confirmed by co-oximetry; the PaO₂ of 245 mmHg on 100% O₂ confirms oxygen is being delivered to the lungs but cannot be carried by the methemoglobin-containing blood; treatment is required.

6. A 38-year-old man presents with a fluctuant periapical abscess on the lower right first molar. The dentist performs an inferior alveolar nerve block (IANB) with lidocaine 2% with epinephrine 1:100,000, achieving expected lip numbness but no pain relief at the tooth. The patient cannot tolerate the procedure. The dentist considers injecting lidocaine directly into the abscess cavity before attempting incision and drainage. Which of the following best predicts the pharmacologic outcome of direct intra-abscess injection and explains the mechanism?

A) Direct intra-abscess injection will be fully effective because it delivers the local anesthetic in higher concentration directly adjacent to the periapical nerve fibers; the failure of the IANB reflects inadequate drug spread to the apex, not any intrinsic resistance of the tissue; direct injection bypasses this anatomic limitation.
B) Direct intra-abscess injection will work more effectively than the nerve block because the epinephrine component produces local vasoconstriction that retains lidocaine at the injection site longer than at the nerve block site, and the acidic environment of the abscess actually accelerates ester-class hydrolysis of lidocaine's metabolites, prolonging the duration of action.
C) Direct intra-abscess injection will also fail or provide only partial anesthesia; the pus-filled cavity has a pH of approximately 5.5–6.5, and lidocaine (pKa 7.9) injected into this environment will be overwhelmingly ionized — with less than 1% in the membrane-permeable free-base form — making it nearly incapable of diffusing across nerve membranes to the sodium channel binding site; the same ionization failure that defeated the IANB at inflamed periapical tissue applies even more severely to drug injected directly into the acidic abscess.
D) Direct intra-abscess injection will succeed where the IANB failed because the abscess cavity is avascular and the local anesthetic injected into it is not absorbed into the systemic circulation; this creates a prolonged depot of drug that slowly re-ionizes at the more alkaline nerve membrane surface, providing sustained anesthesia through an ion-trapping reversal mechanism.
E) Direct intra-abscess injection will fail for a different reason than the IANB failure; while IANB failure is caused by tissue acidosis impairing drug ionization, intra-abscess injection fails because bacterial proteases in the pus irreversibly cleave the amide bond of lidocaine before it can diffuse to the nerve, creating a pharmacologically inert metabolite in higher concentration than the parent compound.

ANSWER: C

Rationale:

Option C is correct. The inferior alveolar nerve block failed because the inflamed periapical tissue surrounding the nerve block injection site has a lower pH than normal tissue — a consequence of bacterial metabolism, ischemia, and inflammatory mediator accumulation. At pH 5.5–6.5, lidocaine (pKa 7.9) is overwhelmingly ionized: the Henderson-Hasselbalch relationship predicts that less than 1% is in the membrane-permeable unionized free-base form at pH 6.0. This near-total ionization prevents diffusion across nerve sheaths and axonal membranes, producing profound resistance to local anesthesia even when the drug is present in the tissue. Injecting lidocaine directly into the abscess cavity subjects the drug to an even more acidic environment (the interior of an abscess may have a pH as low as 5.5) than the periapical tissue surrounding the nerve block. The ionization failure is therefore at least as severe inside the abscess as at the IANB injection site — direct intra-abscess injection would predictably fail by the same mechanism. The practical alternatives are: (1) systemic analgesia to allow the procedure under less-than-perfect anesthesia; (2) intraosseous or intrapulpal injection if feasible, bypassing the abscess environment; (3) waiting for antibiotic reduction of infection before attempting anesthesia; or (4) awake incision under topical anesthesia.

Option A: Option A is incorrect; the IANB failure was not anatomic — the lip numbness confirms adequate drug spread to the nerve; the failure was at the inflamed tooth, not at the nerve. The acidic tissue environment at the apex prevents local anesthetic from working even when the nerve trunk itself is normally anesthetized.
Option B: Option B is incorrect; lidocaine is an amide, not an ester — it is not hydrolyzed by tissue enzymes; and the epinephrine-induced local vasoconstriction, while beneficial for absorption reduction, cannot overcome the profound ionization failure from pH 5.5–6.5.
Option D: Option D is incorrect; the abscess cavity is not avascular — it is surrounded by highly vascular inflamed tissue, and absorbed drug does enter the systemic circulation; and the proposed ion-trapping reversal mechanism is pharmacologically backwards — ion trapping inside the axon (where pH is more alkaline) would trap ionized drug inside the nerve, not enable the drug to enter the nerve from the abscess.
Option E: Option E is incorrect; amide local anesthetics are not cleaved by bacterial proteases at clinically relevant rates; the amide bond is chemically stable under these conditions and the failure mechanism is ionization-based, not enzymatic.

7. During an ultrasound-guided interscalene nerve block with bupivacaine 0.5%, a 58-year-old man develops sudden loss of consciousness followed within 30 seconds by ventricular fibrillation. CPR is immediately initiated. Lipid emulsion 20% is drawn up and a 1.5 mL/kg IV bolus is administered. The team asks whether epinephrine should be given and at what dose. Which of the following correctly identifies the recommended approach to vasopressor use during lipid emulsion resuscitation of bupivacaine-induced LAST?

A) Epinephrine should be used if vasopressor support is needed, but at substantially reduced doses — small boluses of 10–100 μg IV rather than the standard ACLS dose of 1 mg IV every 3–5 minutes; animal data and LAST guidelines from the Association of Anaesthetists and the American Society of Regional Anesthesia indicate that high-dose epinephrine in LAST may worsen outcomes by producing tachyarrhythmias, increasing myocardial oxygen demand, and potentially impairing lipid sink-mediated channel recovery; vasopressin should also be avoided in LAST.
B) Epinephrine should be given at the full standard ACLS dose (1 mg IV every 3–5 minutes) because the lipid emulsion sequesters a clinically significant fraction of each epinephrine bolus in the lipid phase, necessitating higher doses to deliver adequate free epinephrine for cardiac adrenergic receptor stimulation; standard ACLS dosing compensates for this lipid sink effect.
C) Epinephrine is absolutely contraindicated in bupivacaine LAST because its β₁ stimulation in the context of sodium channel-blocked ventricular myocardium predictably precipitates irreversible ventricular fibrillation; lipid emulsion alone is the definitive treatment, and vasopressors of any kind should be withheld until organized rhythm is restored by lipid emulsion.
D) The standard ACLS epinephrine dose (1 mg IV) should be given immediately and repeated every 3–5 minutes; LAST does not require any modification to standard ACLS vasopressor protocols because epinephrine's mechanism of action — β₁ receptor stimulation — is independent of sodium channel blockade and is therefore unaffected by bupivacaine.
E) Phenylephrine should replace epinephrine as the vasopressor of choice in bupivacaine LAST because phenylephrine's pure α₁ mechanism increases coronary perfusion pressure without the tachyarrhythmogenic β₁ effects of epinephrine; phenylephrine should be given at 100–200 μg boluses to support blood pressure while lipid emulsion extracts bupivacaine from cardiac tissue.

ANSWER: A

Rationale:

Option A is correct. Current LAST management guidelines — including those from the Association of Anaesthetists (United Kingdom) and the American Society of Regional Anesthesia and Pain Medicine (ASRA) — specifically recommend that if vasopressor support is needed during bupivacaine LAST resuscitation, epinephrine should be used at substantially reduced doses compared to standard ACLS: small boluses of approximately 10–100 μg IV rather than the 1 mg standard ACLS dose. This recommendation is based on animal model data consistently demonstrating that high-dose epinephrine during LAST resuscitation can worsen outcomes compared to lower doses or lipid emulsion alone. The proposed mechanisms for this detrimental effect include: (1) tachyarrhythmias provoked by adrenergic stimulation of sodium channel-blocked myocardium; (2) increased myocardial oxygen demand at a time of ongoing ischemia; (3) systemic hypertension that alters coronary perfusion pressure dynamics; and (4) potential interference with the lipid sink mechanism. Vasopressin is also specifically cautioned against in LAST guidelines, in contrast to its routine use in standard ACLS. Lipid emulsion should be established as the primary pharmacologic intervention, with vasopressors as a secondary support measure. This represents a deliberate, evidence-informed departure from standard ACLS that is specific to the pharmacologically distinct mechanism of bupivacaine cardiac arrest.

Option B: Option B is incorrect; epinephrine is not substantially sequestered by lipid emulsion because it is a hydrophilic catecholamine with low lipophilicity — the lipid sink is selective for highly lipophilic drugs like bupivacaine, not for catecholamines.
Option C: Option C is incorrect; complete avoidance of epinephrine is not recommended — vasopressor support remains appropriate in LAST resuscitation; the evidence supports dose reduction, not elimination.
Option D: Option D is incorrect; LAST does require modification to standard ACLS vasopressor protocols — the evidence from animal studies and the specificity of LAST guidelines is precisely that standard 1 mg epinephrine doses are potentially harmful in this context.
Option E: Option E is incorrect; phenylephrine as a specific replacement for epinephrine in LAST is not established by current guidelines; the recommendation is for reduced-dose epinephrine, and phenylephrine's theoretical advantage in avoiding tachyarrhythmia is not supported by sufficient clinical evidence to constitute a guideline-level recommendation over small-dose epinephrine.

8. A laboring patient with a well-functioning epidural requires urgent cesarean delivery for non-reassuring fetal heart tracings. The anesthesiologist reaches for epidural chloroprocaine 3% — the standard choice for rapid epidural conversion in this institution — to exploit its near-instantaneous systemic clearance and allow high doses without systemic toxicity risk. As she draws up the chloroprocaine, the circulating nurse flags that the patient's anesthetic record from a prior surgery includes a notation: "prolonged neuromuscular blockade after succinylcholine — possible pseudocholinesterase deficiency." Which of the following correctly describes the impact of this flag on the chloroprocaine plan and the appropriate management decision?

A) The pseudocholinesterase deficiency flag is irrelevant to the chloroprocaine decision because chloroprocaine's safety margin at high epidural doses is based on its low protein binding, not on plasma hydrolysis; in patients with pseudocholinesterase deficiency, chloroprocaine still achieves adequate epidural clearance through renal elimination of unchanged drug.
B) The pseudocholinesterase deficiency does not meaningfully affect chloroprocaine pharmacokinetics at the doses used for epidural conversion; standard epidural chloroprocaine doses (400–600 mg) are well below the systemic toxic threshold regardless of plasma enzyme activity, because the drug must first be absorbed from the epidural space before pseudocholinesterase activity becomes relevant.
C) Pseudocholinesterase deficiency prolongs chloroprocaine's epidural block duration from the usual 45–60 minutes to approximately 3–4 hours, which is actually beneficial for this urgent cesarean delivery because it eliminates the need for repeated epidural dosing; the standard chloroprocaine dose should be given.
D) The pseudocholinesterase deficiency flag requires the anesthesiologist to switch entirely to a general anesthetic because no regional technique is safe in pseudocholinesterase-deficient patients undergoing urgent surgery; the risk of local anesthetic toxicity from any agent is unacceptably high when plasma clearance mechanisms are impaired.
E) This flag is a critical safety concern: chloroprocaine's safety at high epidural doses (800–1000 mg in some protocols) depends entirely on its near-instantaneous plasma hydrolysis by pseudocholinesterase; in a patient with pseudocholinesterase deficiency, the plasma half-life extends from under 60 seconds to potentially minutes or longer, eliminating the kinetic safety advantage that permits high dosing; the anesthesiologist should switch to an amide agent such as lidocaine 2% or bupivacaine 0.5% for the epidural conversion, as amide clearance is hepatic and unaffected by pseudocholinesterase status.

ANSWER: E

Rationale:

Option E is correct. Chloroprocaine's exceptional safety at the high epidural doses used for rapid obstetric surgical conversion rests entirely on one pharmacokinetic property: plasma hydrolysis by pseudocholinesterase (butyrylcholinesterase) with a half-life of under 60 seconds in normal individuals. This near-instantaneous destruction in the bloodstream means that chloroprocaine absorbed from the epidural venous plexus is eliminated before it can accumulate to CNS or cardiac toxic concentrations — a critical safety feature that allows doses of 800–1000 mg to be used safely. In a patient with pseudocholinesterase deficiency (confirmed by the history of prolonged succinylcholine effect, which indicates the same enzyme is responsible for succinylcholine hydrolysis), this kinetic safety net is substantially compromised. The plasma half-life of chloroprocaine extends to minutes or tens of minutes, transforming a drug with instantaneous plasma clearance into one with intermediate persistence. The doses calibrated for instantaneous clearance now carry real systemic toxicity risk. The correct response is to switch to an amide local anesthetic for the epidural conversion. Lidocaine 2% provides rapid epidural onset (appropriate for urgent conversion), and bupivacaine 0.5% provides reliable surgical anesthesia — both are metabolized by hepatic CYP enzymes and are entirely unaffected by pseudocholinesterase status. The urgency of the delivery does not change this pharmacokinetic risk assessment.

Option A: Option A is incorrect; chloroprocaine's safety margin at high doses depends specifically on plasma pseudocholinesterase hydrolysis — not on protein binding or renal elimination; renal clearance of unchanged chloroprocaine is negligible at clinical doses.
Option B: Option B is incorrect; the dose-safety argument for chloroprocaine explicitly depends on the assumption of rapid plasma destruction; without that destruction, absorbed chloroprocaine accumulates and doses that were safe with normal enzyme become toxic without it.
Option C: Option C is incorrect; prolonging the block duration to 3–4 hours is not a benefit — the clinical concern is systemic toxicity from accumulated unhydrolyzed chloroprocaine, not simply extended block duration.
Option D: Option D is incorrect; pseudocholinesterase deficiency does not contraindicate all regional anesthesia — it specifically affects ester agents that rely on pseudocholinesterase for clearance; amide agents are fully safe and the appropriate substitution is amide, not general anesthesia.

9. A 70-year-old woman with post-herpetic neuralgia and Child-Pugh B hepatic cirrhosis is admitted for a trial of intravenous lidocaine infusion for refractory neuropathic pain. She is started at 1.5 mg/kg/hour after a loading dose. At hour 24 she develops mild confusion, dizziness, and perioral tingling. Her serum lidocaine level drawn at that time is 6.2 μg/mL (therapeutic range for analgesia approximately 1.5–5 μg/mL; CNS toxicity typically begins above 5–7 μg/mL). Which of the following correctly identifies the pharmacokinetic basis for this accumulation and the appropriate management adjustment?

A) The accumulation is caused by reduced renal excretion of unchanged lidocaine in elderly patients; lidocaine is primarily eliminated by the kidney in patients over 65, and the normal hepatic clearance pathway is a minor route that becomes relevant only when renal function is compromised; the management is to reduce the infusion rate and monitor renal function.
B) The accumulation reflects saturation of lidocaine's protein binding sites in this elderly patient; at plasma concentrations above 5 μg/mL, albumin binding sites for lidocaine are saturated and the resulting non-linear increase in free fraction produces a disproportionate jump in pharmacodynamic effect; the management is to add albumin infusion to restore protein binding capacity.
C) The accumulation is caused by lidocaine inhibiting its own CYP3A4-mediated metabolism through competitive substrate inhibition; at concentrations above 3 μg/mL, lidocaine's high-affinity binding to CYP3A4 prevents further metabolism, producing a self-limiting accumulation that plateaus once enzyme saturation is complete; no management change is necessary.
D) Lidocaine is an amide local anesthetic with high hepatic extraction that depends on both hepatic blood flow and CYP enzyme activity for its clearance; in this patient, Child-Pugh B cirrhosis substantially reduces both CYP3A4/CYP1A2 enzyme activity and hepatic blood flow, impairing lidocaine clearance and allowing progressive plasma accumulation to toxic concentrations during a 24-hour continuous infusion; the management is to stop or substantially reduce the infusion rate, monitor for progression to seizure or cardiovascular toxicity, and recalculate the infusion rate based on estimated hepatic clearance reduction of 50–70% in Child-Pugh B disease.
E) The accumulation is caused by age-related reduction in volume of distribution; in a 70-year-old patient, reduced total body water and skeletal muscle mass decrease lidocaine's volume of distribution, producing higher plasma concentrations for any given infusion rate without any change in hepatic clearance; the management is to reduce the loading dose only, as the maintenance infusion rate does not require adjustment once volume of distribution effects equilibrate.

ANSWER: D

Rationale:

Option D is correct. Lidocaine is a high-hepatic-extraction amide local anesthetic — under normal conditions, approximately 65–70% of lidocaine is extracted by the liver on each pass, making its clearance highly sensitive to both hepatic blood flow (a flow-limited drug) and hepatic CYP enzyme activity. In a patient with Child-Pugh B hepatic cirrhosis, two independent mechanisms combine to substantially impair lidocaine clearance: (1) reduced intrinsic CYP3A4 and CYP1A2 enzyme activity from hepatocellular dysfunction, reducing the enzymatic capacity to metabolize lidocaine; and (2) reduced portal and hepatic blood flow from cirrhosis-associated portal hypertension and hepatic architectural distortion, reducing the delivery of drug to metabolic enzymes. The 24-hour time course of accumulation is consistent with a drug with a plasma half-life of approximately 1.5–2 hours in normal patients that is substantially prolonged by impaired clearance — multiple half-lives are required to reach elevated steady-state concentrations, and after 24 hours the plasma concentration has risen to the lower CNS-toxic range. The management priorities are to stop or substantially reduce the infusion to halt further accumulation, monitor for progression of CNS toxicity (seizures) and cardiovascular signs, and re-dose at a rate calculated to account for the estimated 50–70% reduction in hepatic clearance characteristic of Child-Pugh B disease.

Option A: Option A is incorrect; lidocaine is not primarily renally eliminated — it is a high-extraction hepatic drug with less than 10% excreted unchanged by the kidney; renal clearance is not the dominant mechanism of lidocaine elimination in any age group.
Option B: Option B is incorrect; lidocaine does have significant protein binding (~65%), but saturable binding kinetics at clinical plasma concentrations are not the mechanism of accumulation — accumulation in hepatic disease is driven by reduced metabolic clearance, not by binding saturation.
Option C: Option C is incorrect; lidocaine does not produce clinically significant self-inhibition of CYP3A4 at therapeutic plasma concentrations; competitive substrate inhibition of this type is not an established mechanism of lidocaine accumulation.
Option E: Option E is incorrect; while reduced volume of distribution in elderly patients does affect the pharmacokinetics of a single dose, the progressive accumulation over 24 hours of continuous infusion is not explained by reduced Vd — that would affect peak concentration after a bolus dose, not the trajectory of accumulation during a continuous infusion; the dominant mechanism of accumulation over time is impaired clearance, not distribution.

10. A 24-year-old competitive collegiate swimmer is undergoing outpatient shoulder labral repair under interscalene nerve block with ropivacaine 0.5%. The surgeon asks the anesthesiologist to administer dexamethasone 8 mg IV for block prolongation and postoperative nausea and vomiting (PONV) prophylaxis. The anesthesiologist notes the patient has no diabetes, no hypertension, no known infection, and no prior corticosteroid exposure. She considers whether any aspect of this patient's specific context modifies the standard risk-benefit assessment for a single perioperative dexamethasone dose. Which of the following correctly identifies the most relevant clinical consideration specific to this patient population?

A) Competitive athletes have higher basal cortisol levels from chronic exercise-induced hypothalamic-pituitary-adrenal axis stimulation; a single dose of dexamethasone 8 mg IV will completely suppress endogenous cortisol production for 48–72 hours through HPA axis feedback inhibition, producing clinically significant adrenal insufficiency during the immediate postoperative period when stress responses are needed.
B) The dexamethasone dose is inappropriate in this patient because competitive swimmers have higher plasma pseudocholinesterase activity from training-induced enzyme upregulation; dexamethasone inhibits pseudocholinesterase and would paradoxically increase the risk of ester local anesthetic toxicity if any ester agent is used for supplemental local anesthesia during the procedure.
C) Competitive athletes and their governing bodies typically prohibit glucocorticoids without a therapeutic use exemption (TUE); while dexamethasone 8 mg IV is pharmacologically appropriate and medically beneficial for this patient, the anesthesiologist should discuss with the patient before administration that perioperative glucocorticoid use may require notification of their sports governing body, and that documentation of the medical indication is important to protect the athlete's eligibility.
D) A single dexamethasone 8 mg IV dose in a young athlete produces dose-dependent tendon collagen inhibition that impairs post-surgical tendon healing; given that this patient is undergoing labral repair, dexamethasone is relatively contraindicated because the collagen synthesis inhibition will directly impair the repaired tissue and compromise surgical outcome.
E) Competitive athletes have significantly higher plasma ropivacaine concentrations than non-athletes at equivalent infusion rates due to increased cardiac output redistributing drug away from hepatic extraction; dexamethasone must be avoided in this patient because it inhibits CYP1A2 through glucocorticoid receptor-mediated downregulation, further elevating ropivacaine plasma levels and increasing LAST risk.

ANSWER: C

Rationale:

Option C is correct. In an otherwise healthy young patient with no metabolic comorbidities, a single perioperative dose of dexamethasone 8 mg IV is pharmacologically and clinically appropriate — the analgesic benefit of extending the interscalene block by 6–8 hours and the PONV prophylaxis are well-established and meaningful for an outpatient surgical patient. However, competitive athletes are subject to anti-doping regulations administered by sports governing bodies such as the World Anti-Doping Agency (WADA) and its affiliated national and sport-specific organizations. Glucocorticoids — including dexamethasone — are prohibited in competition under WADA rules when administered by routes other than topical, inhalational, or certain specific oral indications, and are monitored substances even out of competition. A perioperative intravenous dexamethasone dose constitutes glucocorticoid administration that may require the athlete to file for or have in place a therapeutic use exemption (TUE). Failure to comply with anti-doping notification requirements can result in sanctions even when the administration was medically indicated. This regulatory consideration — not a pharmacologic contraindication — is the most relevant clinical modification to the standard risk-benefit assessment for this specific patient. The anesthesiologist's responsibility is to inform the patient, document the medical indication clearly, and advise the patient to contact their sports governing body regarding TUE requirements.

Option A: Option A is incorrect; HPA axis suppression from a single 8 mg IV dexamethasone dose is real but typically mild and brief (cortisol suppression lasting 24–36 hours rather than 48–72 hours); clinically significant adrenal insufficiency in the immediate postoperative period from a single perioperative dose in a patient with a normal HPA axis is not an established clinical risk.
Option B: Option B is incorrect; dexamethasone does not inhibit pseudocholinesterase, and exercise does not upregulate pseudocholinesterase to a clinically relevant degree; this mechanism is pharmacologically invented.
Option D: Option D is incorrect; while systemic corticosteroids do have effects on collagen metabolism, a single perioperative dose of dexamethasone 8 mg is not established as clinically impairing surgical repair healing; this dose is routinely used in orthopedic procedures without evidence of impaired tissue healing.
Option E: Option E is incorrect; dexamethasone does not inhibit CYP1A2 — glucocorticoids primarily induce CYP3A4 and do not meaningfully downregulate CYP1A2; and increased cardiac output in athletes does not produce the described pharmacokinetic effect on ropivacaine.

11. A 54-year-old woman underwent mastectomy with immediate implant reconstruction. The anesthesia record documents a pectoralis nerve block (PECS block — an interfascial plane block targeting the anterior chest wall) with bupivacaine 0.25% with epinephrine 1:200,000, total volume 40 mL. On postoperative day 1, she complains of blue-gray discoloration and numbness of the index and middle fingers of the ipsilateral hand. The surgical team asks whether the epinephrine in the block solution could have caused this digital ischemia. Which of the following correctly assesses whether the epinephrine contributes to this complication?

A) The epinephrine is the most likely cause of the digital ischemia; epinephrine 1:200,000 used in peripheral nerve blocks is known to produce distal vascular spasm extending several dermatomes beyond the injection site through sympathetic reflex arcs activated by α₁ receptor stimulation; this is a recognized complication of epinephrine-containing blocks near the brachial plexus.
B) Epinephrine at 1:200,000 concentration in a PECS block is extremely unlikely to have caused digital ischemia; the PECS block targets the interfascial plane of the anterior chest wall — anatomically distant from the digital arteries — and epinephrine at this concentration and route produces local vasoconstriction at the injection site, not systemic or remote vascular spasm; the digital ischemia more likely reflects a vascular complication of the surgery itself (retraction, positional compression, or vascular injury) or the implant reconstruction rather than a consequence of a distant fascial plane block with dilute epinephrine.
C) Epinephrine 1:200,000 in a 40 mL PECS block injects a total of 200 μg of epinephrine, which is sufficient for systemic absorption to produce reflex digital artery vasoconstriction via circulating catecholamine elevation; the digital ischemia is therefore a direct pharmacodynamic consequence of the systemically absorbed epinephrine fraction from the fascial plane block.
D) The digital ischemia is caused by the bupivacaine component of the block, not the epinephrine; bupivacaine at 0.25% concentration in a fascial plane block is absorbed into the brachial plexus vascular bed and produces vasospasm of the digital arteries through its direct vascular smooth muscle calcium channel blocking effect, which is independent of adrenergic receptor activation.
E) The epinephrine may have contributed through a pharmacokinetic mechanism: the 1:200,000 epinephrine concentration prolongs bupivacaine's local tissue residence to over 24 hours in fascial plane blocks, and the prolonged bupivacaine exposure produces cumulative sympathetic nerve blockade of the brachial plexus, paradoxically causing digital vasospasm through loss of sympathetic vasodilatory tone.

ANSWER: B

Rationale:

Option B is correct. The concern that epinephrine in a regional block caused remote digital ischemia does not withstand pharmacologic scrutiny in this clinical context. Epinephrine is contraindicated for use at end-arterial anatomic sites — the digits, penis, pinna, and nasal tip — because direct injection of epinephrine into these terminal vascular beds produces local vasoconstriction without collateral backup, risking ischemia. However, the PECS block is performed in the interfascial plane of the anterior chest wall, which is anatomically and vascularly remote from the digital arteries. Epinephrine at 1:200,000 concentration (5 μg/mL) in a fascial plane block produces local vasoconstriction at the injection site — this is its intended mechanism for slowing local anesthetic absorption and prolonging block duration. It does not produce remote vascular spasm at the digits through any established pharmacologic mechanism; the catecholamine concentration reaching the digital arteries via systemic absorption from a fascial plane block is far below any vasoactive threshold. The total epinephrine in the block (40 mL × 5 μg/mL = 200 μg) would, if absorbed over the course of hours, produce a vanishingly small circulating concentration distributed in the total blood volume. The digital ischemia in this patient requires investigation for surgical causes — vascular injury during dissection, positional compression of the brachial plexus or axillary vessels during the procedure, implant-related compression of neurovascular structures, or thrombosis — not epinephrine from a distant fascial plane block.

Option A: Option A is incorrect; epinephrine does not produce sympathetic reflex arcs causing distal vascular spasm several dermatomes from the injection site — this is not an established pharmacologic mechanism of epinephrine at regional anesthesia doses.
Option C: Option C is incorrect; 200 μg of epinephrine absorbed over several hours from a fascial plane block distributes into approximately 5 liters of blood, producing a circulating concentration of approximately 0.04 μg/mL — far below the threshold for systemic adrenergic vasoconstriction; this calculation demonstrates why systemic absorption from regional block doses does not produce hemodynamic effects at remote vascular beds.
Option D: Option D is incorrect; bupivacaine at local anesthetic concentrations does not produce vasospasm of digital arteries through a calcium channel blocking mechanism — bupivacaine is a sodium channel blocker with incidental vascular effects at clinical concentrations; calcium channel-mediated digital vasospasm is not an established complication of fascial plane blocks with bupivacaine.
Option E: Option E is incorrect; prolonged bupivacaine tissue residence from epinephrine does not produce cumulative sympathetic blockade of the brachial plexus causing digital vasospasm — this mechanism conflates the pharmacology of neuraxial sympathetic blockade with the much more limited autonomic effects of a fascial plane block.